A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer.

BMC Surgery
Andre MihaljevicMichael Geissler

Abstract

Pancreatic cancer is the fourth most common cause of cancer related death in Western countries. Advantages in surgical techniques, radiation and chemotherapy had almost no impact on the long term survival of affected patients. Therefore, the need for better treatment strategies is urgent. HER2, a receptor tyrosine kinase of the EGFR family, involved in signal transduction pathways leading to cell growth and differentiation is overexpressed in a number of cancers, including breast and pancreatic cancer. While in breast cancer HER2 has already been successfully used as a treatment target, there are only limited data evaluating the effects of inhibiting HER2 tyrosine kinases in patients with pancreatic cancer. Here we report the design of a prospective, non-randomized multi-centered Phase II clinical study evaluating the effects of the Fluoropyrimidine-carbamate Capecitabine (Xeloda) and the monoclonal anti-HER2 antibody Trastuzumab (Herceptin) in patients with non-resectable, HER2 overexpressing pancreatic cancer. Patients eligible for the study will receive Trastuzumab infusions on day 1, 8 and 15 concomitant to the oral intake of Capecitabine from day 1 to day 14 of each three week cycle. Cycles will be repeated until tumor pro...Continue Reading

References

Mar 1, 1989·Controlled Clinical Trials·R Simon
May 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J HjermstadS Kaasa
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H A BurrisD D Von Hoff
Apr 5, 2001·Clinical Pharmacokinetics·B ReignerE Weidekamm
May 2, 2001·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·P BüchlerO J Hines
Oct 5, 2001·American Journal of Clinical Oncology·H SafranU Tantravahi
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas H CartwrightJoseph J Schulz
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Viviane HessRichard Herrmann
Mar 19, 2004·The New England Journal of Medicine·John P NeoptolemosUNKNOWN European Study Group for Pancreatic Cancer
May 20, 2004·Journal of the National Cancer Institute·Mark D PegramDennis J Slamon
Dec 8, 2004·Cancer Investigation·Howard SafranTeresa Kennedy
Jul 21, 2005·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Megan Dann FesinmeyerDeborah J Bowen
Jan 19, 2006·Cancer Chemotherapy and Pharmacology·Søren Astrup Jensen, Jens Benn Sørensen
Aug 18, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kenjiro KimuraKosei Hirakawa
Mar 16, 2007·Neoplasia : an International Journal for Oncology Research·Peter BüchlerOscar J Hines
Jun 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard HerrmannUNKNOWN Central European Cooperative Oncology Group
Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Asma SultanaPaula Ghaneh
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Aug 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jürg BernhardUNKNOWN Central European Cooperative Oncology Group

❮ Previous
Next ❯

Citations

Jun 22, 2010·TheScientificWorldJournal·Patrick ChamesDaniel Baty
Mar 4, 2010·The AAPS Journal·Jing LiJessie L-S Au
Jul 27, 2010·Human Pathology·Andreas H MarxJakob R Izbicki
Sep 8, 2019·International Journal of Molecular Sciences·Hongmei XiaoXinjian Chen

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection

Related Concepts

Related Feeds

Cancer Imaging

Imaging techniques, including CT and MR, have become essential to tumor detection, diagnosis, and monitoring. Here is the latest research on cancer imaging.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Atrophic Gastritis

Atrophic Gastritis is a process where gastric glandular cells are lost and replaced with firbous tissues, as a result of chronic inflammation. Learn more about Atrophic Gastritis here.